Cardiometabolic diseases are the most common cause of death worldwide. The main goal of our group is to identify novel molecular mechanisms of development of calcific aortic valve disease and to reveal the effects of maternal cardiometabolic diseases on placental molecular processes and metabolic programming. Molecular mechanisms of calcific aortic valve disease: Calcific aortic valve disease (CAVD) is the most common form of valvular heart disease and the second-leading cause of cardiovascular mortality. CAVD is a slowly progressing disorder that ranges from mild valve thickening to severe calcification called aortic stenosis. There is no pharmacologic treatment for CAVD and only curative therapy of the disease is valve replacement. In our research, we provide translational insights in the development of aortic stenosis allowing identification of novel target therapies and diagnostic tools for CAVD. The effects of maternal cardiometabolic diseases on placental molecular processes and metabolic reprogramming: There is an increasing number of obese women of reproductive age, thus maternal overweight and obesity are resulting in negative outcomes for both women and foetuses including gestational hypertension, gestational diabetes, preeclampsia and preterm birth. Growing evidence links individuals susceptibility to chronic disease in adult life to events during his/her intrauterine phase of development. Our aim is to determine how maternal cardiometabolic disorders affect placental molecular processes and metabolic programming. The study material is obtained from Kuopio Birth Cohort platform (www.KuBiCo.fi).